ScholarX

Journal of Clinical Oncology

Journal Title

  • Journal of Clinical Oncology

ISSN

  • E 1527-7755 | P 0732-183X

Publisher

  • American Society of Clinical Oncology

Listed on(Coverage)

JCR 1997-2023
SJR 1999-2020;2022-2023
CiteScore 2011-2023
SCI 2010-2019
SCIE 2010-2024
CC 2016-2024
SCOPUS 2017-2024
MEDLINE 2016-2024
EMBASE 2016-2024

Active

  • Active

    based on the information

    • SCOPUS:2024-10

Country

  • USA

Aime & Scopes

  • JCO publishes original research, reviews and other material related to breast cancer, gastrointestinal cancer, hematologic malignancies, molecular oncology, lung cancer, genitourinary cancer, head and neck cancer, pediatric oncology, neurooncology, supportive care and quality of life issues, prevention, and phase I and clinical pharmacology. Its readership comprises practicing clinical oncologists, researchers, students, individuals in training, and allied health professionals throughout the world. Members of the American Society of Clinical Oncology as well as nonmember subscribers and patrons of medical libraries globally utilize the groundbreaking research published in each issue of JCO.

Homepage

Article List

1 - 20 out of 1,022 results.

SCIESCOPUS
Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations Results From the Phase II TROPION-Lung05 Study

Sands, Jacob; Ahn, Myung-Ju; Lisberg, Aaron; Cho, Byoung Chul; Blumenschein, George; Shum, Elaine; Tostivint, Elvire Pons; Goto, Yasushi; Yoh, Kiyotaka; Heist, Rebecca, et al.

ArticleIssue Date2025CitationJournal of Clinical Oncology, v.43, no.10PublisherLippincott Williams and Wilkins
SCIESCOPUS
Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma

Bartlett, Nancy L.; Hahn, Uwe; Kim, Won-Seog; Fleury, Isabelle; Laribi, Kamel; Bergua, Juan-Miguel; Bouabdallah, Krimo; Forward, Nicholas; Bijou, Fontanet; MacDonald, David, et al.

ArticleIssue Date2025CitationJournal of Clinical Oncology, v.43, no.9PublisherLippincott Williams and Wilkins
SCIESCOPUS
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trialopen access

Marth, Christian; Moore, Richard G.; Bidzinski, Mariusz; Pignata, Sandro; Ayhan, Ali; Rubio, M. Jesus; Beiner, Mario; Hall, Marcia; Vulsteke, Christof; Braicu, Elena Ioana, et al.

ArticleIssue Date2025CitationJOURNAL OF CLINICAL ONCOLOGY, v.43, no.9, pp 1083 - 1100PublisherLIPPINCOTT WILLIAMS & WILKINS
SCIESCOPUS
Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial

Macarulla, Teresa; Ren, Zhenggang; Chon, Hong Jae; Park, Joon Oh; Kim, Jin Won; Pressiani, Tiziana; Li, Daneng; Zhukova, Lyudmila; Zhu, Andrew X.; Chen, Ming-Huang, et al.

ArticleIssue Date2025CitationJournal of Clinical Oncology, v.43, no.5PublisherLippincott Williams and Wilkins
SCIESCOPUS
Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274.

Milowsky, Matthew I.; Galsky, Matthew D.; Witjes, Johannes Alfred; Gschwend, Juergen E.; Schenker, Michael; Perez Valderrama, Begona; Tomita, Yoshihiko; Bamias, Aristotelis; Lebret, Thierry; Shariat, Shahrokh F., et al.

ArticleIssue Date2025CitationJOURNAL OF CLINICAL ONCOLOGY, v.43, no.5_SUPPLPublisherLIPPINCOTT WILLIAMS & WILKINS
SCIESCOPUS
KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and novel immunotherapy agents for advanced clear cell renal cell carcinoma (ccRCC).

Suarez, Cristina; Albiges, Laurence; Beckermann, Katy; Hammers, Hans J.; Stadler, Walter Michael; Miller Jr, Wilson H.; Rojas, Carlos; Peer, Avivit; Goh, Jeffrey C.; Park, Se Hoon, et al.

ArticleIssue Date2025CitationJOURNAL OF CLINICAL ONCOLOGY, v.43, no.5_SUPPL, pp 552 - 552PublisherLIPPINCOTT WILLIAMS & WILKINS
SCIESCOPUS
EV-302: Updated analysis from the phase 3 global study of enfortumab vedotin in combination with pembrolizumab (EV plus P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC).

Powles, Thomas; van der Heijden, Michiel Simon; Loriot, Yohann; Bedke, Jens; Valderrama, Begona P.; Iyer, Gopa; Kikuchi, Eiji; Hoffman-Censits, Jeannie; Vulsteke, Christof; Drakaki, Alexandra, et al.

ArticleIssue Date2025CitationJOURNAL OF CLINICAL ONCOLOGY, v.43, no.5_SUPPLPublisherLIPPINCOTT WILLIAMS & WILKINS
SCIESCOPUS
KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC).

Albiges, Laurence; Suarez, Cristina; Powles, Thomas; Motzer, Robert J.; Stadler, Walter Michael; Miller Jr, Wilson H.; Rojas, Carlos; Peer, Avivit; Goh, Jeffrey C.; Park, Se Hoon, et al.

ArticleIssue Date2025CitationJOURNAL OF CLINICAL ONCOLOGY, v.43, no.5_SUPPL, pp 440 - 440PublisherLIPPINCOTT WILLIAMS & WILKINS
SCIESCOPUS
Second-line platinum-based chemotherapy (PBT) in patients with metastatic urothelial carcinoma (mUC) treated with first-line pembrolizumab plus enfortumab vedotin (P/EV): A single-center, retrospective study.

Kim, Junkyu; Park, Se Hoon; Kim, Changgon; Hyeon, Jiyeon; Lim, Sung Hee; Kwon, Minsuk

ArticleIssue Date2025CitationJOURNAL OF CLINICAL ONCOLOGY, v.43, no.5_SUPPLPublisherLIPPINCOTT WILLIAMS & WILKINS
SCIESCOPUS
Update of phase 1b/2 study of muzastotug (ADG126, an anti-CTLA-4 SAFEbody) in combination with pembrolizumab in advanced/metastatic MSS CRC.

Li, Daneng; Kim, Sun Young; Kim, Hee Kyung; Sharma, Sunil; Shin, Sang Joon; Lee, Jeeyun; Han, Sae-Won; Fakih, Marwan; Chung, Luke Euichul; Li, Yan, et al.

ArticleIssue Date2025CitationJOURNAL OF CLINICAL ONCOLOGY, v.43, no.4_SUPPL, pp 193 - 193PublisherLIPPINCOTT WILLIAMS & WILKINS
SCIESCOPUS
Pembrolizumab or placebo plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: An updated analysis of KEYNOTE-859 for patients enrolled in Asia.

Yen, Chia Jui; Oh, Do-Youn; Bai, Yuxian; Ryu, Min-Hee; Lee, Jeeyun; Li, Jin; Yang, Lin; Yasui, Hisateru; Yabusaki, Hiroshi; Lam, Ka On, et al.

ArticleIssue Date2025CitationJOURNAL OF CLINICAL ONCOLOGY, v.43, no.4_SUPPL, pp 464 - 464PublisherLIPPINCOTT WILLIAMS & WILKINS
SCIESCOPUS
Current status and treatment outcomes of intraductal papillary mucinous carcinoma in Korea: A multi-center cohort study.

Lim, Hee-Eon; Lee, Jong-chan; Paik, Woo Hyun; Lee, Yoon Suk; Choi, Jin Ho; Park, Joo Kyung Sophie; Choi, Young Hoon; Lee, Kang Won; Lee, Jae Min; Kim, Hyeonki, et al.

ArticleIssue Date2025CitationJOURNAL OF CLINICAL ONCOLOGY, v.43, no.4_SUPPL, pp 812 - 812PublisherLIPPINCOTT WILLIAMS & WILKINS
SCIESCOPUS
CLARITY-Gastric 01: A randomized phase 3 study of AZD0901, a Claudin18.2 (CLDN18.2)-targeted antibody-drug conjugate, in second- or later-line (2L+) advanced gastric or gastroesophageal junction cancer (GC/GEJC).

Janjigian, Yelena Y.; Shitara, Kohei; Elimova, Elena; Zhang, Jun; Chen, Ming-Huang; Smyth, Elizabeth Catherine; Lee, Jeeyun; Miao, Rui; Liu, Silver; Holmblad, Marielle, et al.

ArticleIssue Date2025CitationJOURNAL OF CLINICAL ONCOLOGY, v.43, no.4_SUPPL, pp TPS507 - TPS507PublisherLIPPINCOTT WILLIAMS & WILKINS
SCIESCOPUS
Final analysis of the randomized phase 2 part of the ASPEN-06 study: A phase 2/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric/gastroesophageal cancer (GC).

Shitara, Kohei; Wainberg, Zev A.; Tabernero, Josep; Van Cutsem, Eric; Coutzac, Clelia; De La Fouchardiere, Christelle; Lee, Jeeyun; Rha, Sun Young; Kang, Yoon-Koo; Fanning, Philip, et al.

ArticleIssue Date2025CitationJOURNAL OF CLINICAL ONCOLOGY, v.43, no.4_SUPPL, pp 332 - 332PublisherLIPPINCOTT WILLIAMS & WILKINS
SCIESCOPUS
Organ-specific responses to nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma: A multicenter, retrospective study.

Kim, Youngun; Kim, Jung Sun; Kang, Beodeul; Kim, Ilhwan; Kim, Hyeyeong; Lee, Won Suk; Jung, Sanghoon; An, Chansik; Kim, Han Sang; Kim, Chang Gon, et al.

ArticleIssue Date2025CitationJOURNAL OF CLINICAL ONCOLOGY, v.43, no.4_SUPPL, pp 543 - 543PublisherLIPPINCOTT WILLIAMS & WILKINS
SCIESCOPUS
Individual patient data (IPD) pooled analysis on the optimal therapeutic management of patients with microsatellite instability-high (MSI) resectable gastroesophageal adenocarcinoma (GEA)

Raimondi, Alessandra; Tine', Gabriele; Tougeron, David; Lonardi, Sara; Ricagno, Gianmarco; Cardellino, Giovanni Gerardo; Nappo, Floriana; De Vita, Ferdinando; Nankivell, Matthew Guy; Cunningham, David, et al.

ArticleIssue Date2025CitationJOURNAL OF CLINICAL ONCOLOGY, v.43, no.4_SUPPL, pp 455 - 455PublisherLIPPINCOTT WILLIAMS & WILKINS
SCIESCOPUS
Updated results from the trastuzumab deruxtecan (T-DXd) 5.4 mg/kg triplet combination of DESTINY-Gastric03 (DG-03): First-line (1L) T-DXd with fluoropyrimidine (FP) and pembrolizumab in advanced/metastatic HER2-positive (HER2+) esophageal adenocarcinoma, gastric cancer (GC), or gastroesophageal junction adenocarcinoma (GEJA).

Janjigian, Yelena Y.; Van Laarhoven, Hanneke W. M.; Rha, Sun Young; Kozlov, Vadim; Oh, Do-Youn; Gravina, Adriano; Rapatoni, Liane; Shoji, Hirokazu; Hofheinz, Ralf Dieter; Chen, Li-Tzong, et al.

ArticleIssue Date2025CitationJOURNAL OF CLINICAL ONCOLOGY, v.43, no.4_SUPPL, pp 448 - 448PublisherLIPPINCOTT WILLIAMS & WILKINS
SCIESCOPUS
Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: Extended follow-up of a randomized controlled trial and post-treatment immune cell profiling.

Lee, Jeong-Hoon; Park, Youngsu; Shin, Hyunjae; Song, Byeong Geun; Choi, Won-Mook; Han, Hyung Joon; Lee, Youngwoo; Song, Tae-Jin; Yeon, Jong-Eun; Lim, Young-Suk, et al.

ArticleIssue Date2025CitationJOURNAL OF CLINICAL ONCOLOGY, v.43, no.4_SUPPL, pp 518 - 518PublisherLIPPINCOTT WILLIAMS & WILKINS
SCIESCOPUS
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy in patients with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma enrolled in the Republic of Korea: KEYNOTE-859.

Rha, Sun Young; Lee, Jeeyun; Ryu, Min-Hee; Yin, Lina; Leconte, Pierre; Bhagia, Pooja; Oh, Do-Youn

ArticleIssue Date2025CitationJOURNAL OF CLINICAL ONCOLOGY, v.43, no.4_SUPPL, pp 428 - 428PublisherLIPPINCOTT WILLIAMS & WILKINS
SCIESCOPUS
A phase 2 study to assess the safety and efficacy of FLX475 (tivumecirnon) combined with pembrolizumab in patients with advanced or metastatic gastric cancer.

Oh, Do-Youn; Ryu, Min-Hee; Hwang, Jun-Eul; Cho, Jaeyong; Zang, Dae Young; Oh, Sang Cheul; Lee, Jeeyun; Lee, Keun-Wook; Rha, Sun Young; Shim, Byoung Yong, et al.

ArticleIssue Date2025CitationJOURNAL OF CLINICAL ONCOLOGY, v.43, no.4_SUPPLPublisherLIPPINCOTT WILLIAMS & WILKINS
1 2 3 4 5 6 7 8 9 10 last
STATISTICS
Total View:
Daily View:

RSS_1.0 RSS_2.0 ATOM_1.0

CONTACT US

(03063) 25-2, SUNGKYUNKWAN-RO, JONGNO-GU, SEOUL, KOREA samsunglib@skku.edu

COPYRIGHT © 2021 SUNGKYUNKWAN UNIVERSITY ALL RIGHTS RESERVED.

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

BROWSE

한국어